Literature DB >> 22334720

Proadrenomedullin N-terminal 20 peptide increases kinesin's velocity both in vitro and in vivo.

Ignacio M Larráyoz1, Alfredo Martínez.   

Abstract

Intracellular cargo transport relies on microtubules and motor proteins such as kinesins and dyneins. Currently we have ample knowledge of the mechanisms by which motor proteins propel themselves along the microtubules, but little is known about intracellular factors that regulate motor speed. Here we show that proadrenomedullin N-terminal 20 peptide (PAMP) increases kinesin velocity and ATP consumption in a dose-dependent manner, using a variety of human kinesins. Structure-activity studies found that the terminal amide of PAMP is required for modulating kinesin activity and that the smallest peptide fragment retaining this role is PAMP₁₂₋₂₀. On the other hand, peptide fragments as small as PAMP₁₈₋₂₀ maintained the ability of delaying tubulin polymerization, another function previously described for PAMP, indicating that these two activities depend on different regions of the molecule. To demonstrate that these observations are also relevant in vivo, hippocampal neurons were isolated from mice lacking the gene coding for PAMP and from wild type littermates. Intravital stains followed by time-lapse microscopy analysis revealed that mitochondrial speed inside neurons lacking PAMP was significantly slower than in cells expressing the peptide. External addition of synthetic PAMP reversed this phenotype in PAMP-null neurons. Besides the obvious implications for better understanding cell biology, these results may be also relevant for the rapidly evolving discipline of nanotechnology because PAMP may be used as an accelerator of nanodevices based on microtubules and motor proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334720     DOI: 10.1210/en.2011-1685

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Genetic loss of proadrenomedullin N-terminal 20 peptide (PAMP) in mice is compatible with survival.

Authors:  Brooke C Matson; Manyu Li; Claire E Trincot; Elizabeth S Blakeney; Stephanie L Pierce; Kathleen M Caron
Journal:  Peptides       Date:  2018-12-08       Impact factor: 3.750

2.  Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Maite Solas; Alfredo Martínez; María J Ramírez; Francisco J Gil-Bea
Journal:  Mol Neurobiol       Date:  2018-04-18       Impact factor: 5.590

3.  Secreted Amyloid Precursor Protein Alpha, a Neuroprotective Protein in the Brain Has Widespread Effects on the Transcriptome and Proteome of Human Inducible Pluripotent Stem Cell-Derived Glutamatergic Neurons Related to Memory Mechanisms.

Authors:  Katie Peppercorn; Torsten Kleffmann; Owen Jones; Stephanie Hughes; Warren Tate
Journal:  Front Neurosci       Date:  2022-05-26       Impact factor: 5.152

Review 4.  Adrenomedullin, a Novel Target for Neurodegenerative Diseases.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Francisco J Gil-Bea; Alfredo Martínez; María J Ramírez
Journal:  Mol Neurobiol       Date:  2018-03-29       Impact factor: 5.590

5.  Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling.

Authors:  Ghizlane Khalfaoui-Bendriss; Nadège Dussault; Samantha Fernandez-Sauze; Caroline Berenguer-Daizé; Romain Sigaud; Christine Delfino; Mylène Cayol; Philippe Metellus; Olivier Chinot; Kamel Mabrouk; Pierre-Marie Martin; L'Houcine Ouafik
Journal:  Oncotarget       Date:  2015-04-10

6.  Adrenomedullin Contributes to Age-Related Memory Loss in Mice and Is Elevated in Aging Human Brains.

Authors:  Ignacio M Larrayoz; Hilda Ferrero; Eva Martisova; Francisco J Gil-Bea; María J Ramírez; Alfredo Martínez
Journal:  Front Mol Neurosci       Date:  2017-11-15       Impact factor: 5.639

7.  Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer's Disease.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Eva Martisova; Maite Solas; David R Howlett; Paul T Francis; Francisco J Gil-Bea; Alfredo Martínez; María J Ramírez
Journal:  Mol Neurobiol       Date:  2017-09-02       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.